Key Statistics for ATLN
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (CHF) (ttm)
|Est. EPS (CHF) (12/2013)
|Est. PEG Ratio
|Market Cap (M CHF)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|Cash Dividend (CHF)
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ATLN
- Net Income (M/CHF)
Actelion Ltd. is a pharmaceutical company that develops and markets synthetic small-molecule drugs against diseases related to the endothelium. The Company's drugs, Veletri and Tracleer, are used in the treatment of heart and pulmonary conditions.
More Company Profile & Key Executives for ATLN
|Jean-Paul ClozelCEO/Co-Founder||Andre C MullerChief Financial Officer|
|Otto SchwarzExec VP/COO||Guy BraunsteinExec VP/Head:Clinical Dev|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.